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Antibiotic overuse contributes to the emergence of antibiotic-resistant pathogens [1] . Reducing unnecessary antibiotic use in critically ill patients with suspected but unproven infection presents an ongoing challenge. Procalcitonin (PCT) is a blood biomarker that can help discriminate between infectious and noninfectious causes of critical illness [2, 3] and can aid in guiding decisions for the initiation and/or continuation of antibiotics. Although PCT-guided algorithms have been associated with safe reductions in antibiotic exposure in clinical trials [4] [5] [6] [7] , several studies have [8, 9] found that the benefits of PCT-guided treatment observed in trials might be incompletely realized in "real-world" clinical settings.
In August 2012, the PCT assay was introduced at the Children's Hospital of Philadelphia (CHOP) for routine clinical care (see Supplementary Text for details). General education on test characteristics and utility was provided to clinicians with the intent of reducing antibiotic use in the pediatric intensive care unit (PICU). We used no formal algorithm to guide measurement, interpretation, and application of the PCT testing. Our goal was to assess whether introduction of the PCT assay into clinical practice would reduce antibiotic use in children admitted to the PICU.
METHODS

Study Design and Population
We performed a retrospective study of patients admitted to the 55-bed PICU at CHOP between February 1, 2011, and February 28, 2014. We excluded patients who had received systemic antibiotics at CHOP in the 7 days before PICU admission. Data were obtained from our Virtual PICU System database [10] and electronic health records. Data included patient demographics, comorbid conditions, source of and reason for PICU admission, receipt of mechanical ventilation, Pediatric Risk of Mortality III (PRISM-III) score [11] , antibiotic administration, and PCT values. The CHOP Institutional Review Board approved this study.
Outcomes
We examined the (1) initiation of systemic antibiotic therapy in the 24 hours before through 48 hours after PICU admission and (2) continuation of antibiotics for >72 hours among patients who started antibiotic therapy.
Analysis
We used a time-series analysis to examine temporal trends in PICU antibiotic use before and after the PCT assay was performed and a matched-cohort analysis in which patients for whom a PCT test was performed were matched to similar patients for whom a PCT test was not performed. In the time-series analysis, we modeled the trajectory of antibiotic utilization by using a longitudinal piecewise logistic model [12] and using Wald tests to assess changes in trends (slope) before and after PCT assay availability in August 2012, excluding the 2-month (September through October 2012) "phase-in" period, so that unusual immediate changes in behavior did not exert a strong influence on the trend. Standard errors were adjusted to account for multiple PICU admissions for the same patient within a single hospital admission. The matched analysis included patients admitted after the PCT assay was available (August 2012). Each child for whom an initial PCT assay was performed within 48 hours before or after PICU admission (exposed) was matched to a child for whom a PCT assay was not performed (unexposed) by minimizing the within-pair distance on covariates using the Mahalanobis distance [13, 14] and exactly matching on PICU admission diagnosis category (gastrointestinal/hepatic, neurologic, infectious, cardiovascular, trauma, respiratory, ingestion/poisoning, endocrinologic/ metabolic/electrolytic, genitourinary, renal, hematologic/ oncologic, surgical, allergy/immunologic/rheumatologic, musculoskeletal including skin, psychiatric, other) to ensure that patients with the same clinical diagnosis were identical within matched pairs. Covariates included age (continuous), black race, Pediatric Risk of Mortality III score (continuous), chronic ventilator-dependent respiratory failure, oncologic comorbidity, new mechanical ventilation in first hour of PICU admission, PICU admission source, and surgery or trauma preceding PICU admission. Covariate balance after matching was assessed using standardized differences [15, 16] . Risk differences (RDs) were assessed using the McNemar test for matched pairs. We conducted sensitivity analyses to assess the magnitude of bias from an unmeasured confounder that would need to be present to alter our findings [17, 18] (see supplementary text for more details on matching algorithm, assessing balance, and sensitivity analysis).
Statistical tests were 2-sided, and the significance threshold was P < .05. Analyses were performed using R 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria) with the mipmatch package [19] and Stata 13.2 (StataCorp, College Station, Texas).
RESULTS
Time-Series Analysis
A total of 10 135 PICU encounters occurred during the study period (4901 before PCT assay availability, 572 during the 2-month phase-in period, and 4662 after PCT assay availability). During the phase-in period, 30 (5.2%) PICU encounters included an initial PCT test performed within 48 hours before or after PICU admission. Use increased to 10.4% (485) after the phase-in period. Most admissions (350 [72%]) included 1 PCT assay; 14% (69) included 2 tests, and 14% (66) included >2 serial assays. Antibiotics were initiated for 44% of encounters before and 47% of encounters after availability of the PCT assay. Among encounters that included the initiation of antibiotics, 43% and 40% continued antibiotics for >72 hours before and after PCT availability, respectively (see Supplementary Figure 1 , histogram). We found no statistical difference in the trajectories of antibiotic initiation (P = .29) or continuation of antibiotics >72 hours (P = .65) between the periods before PCT assay availability and after PCT assay availability (Figure 1 ).
Matched Analysis
Among 5058 PICU encounters successfully linked to the Virtual PICU System database after PCT assay availability, 506 (10%) included PCT testing at PICU admission. For assessment of antibiotic initiation, 988 encounters were matched (494 exposed and 494 unexposed) with successful covariate balance (see Supplementary Table 1 ). Antibiotics were initiated in 85.2% of PCT-exposed encounters and 64.9% in PCTunexposed encounters (RD, 20.2% [95% confidence interval, 15.4%-24.9%]; P < .001). To assess the continuation of antibiotics for >72 hours among the 2345 PICU encounters in which antibiotics were initiated, 842 encounters were matched, including 421 of 427 exposed and 421 unexposed, with successful balance (see Supplementary Table 2 ). Antibiotics were continued >72 hours in 51.1% of the PCT-exposed encounters and 39.9% of the PCT-unexposed encounters (RD, 11.1% [95% confidence interval, 4.9-17.3]; P < .001).
A sensitivity analysis revealed that an unobserved binary confounder would have had to nearly triple the odds (2.9) of a PCT assay being performed for the patient to remove the observed association between PCT testing and antibiotic initiation. For continuation of antibiotics, a confounder that increased the odds of both having a PCT test performed and antibiotic continuation by 1.29 would remove the observed association between PCT testing and antibiotic continuation.
DISCUSSION
In this retrospective study, we assessed the effect of introducing the PCT assay on antibiotic use in critically ill children. We found no change in antibiotic use over time relative to introduction of the PCT assay. We also found increased use in children for whom PCT was measured, which might be explained by residual confounding by indication or severity of illness, but this result raises concern that the availability of PCT testing might have promoted antibiotic use. Thus, use of the PCT assay, in the absence of a standardized algorithm to guide testing and clinical decision-making, did not have the intended effect of reducing antibiotic use in a real-world critical care setting.
Before introduction of the PCT assay, clinicians were educated about the test characteristics of PCT and the evidence supporting its discriminatory value to distinguish between bacterial and nonbacterial infections; however, a formal algorithm was not implemented. Previous studies found that potentially useful diagnostic testing can be ineffective in the absence of decision-support guidance or a clinical pathway [20] . In our study, most encounters included a PCT assay, which might indicate a lack of knowledge that current evidence from critical care supports serial PCT testing. Therefore, our results suggest that introducing the assay without an algorithm to direct its use and interpretation might not have the intended effect.
Although trials have shown that PCT-guided therapy can reduce antibiotic use [4] [5] [6] [7] , few observational studies have assessed its real-world effect in clinical settings. An observational study indicated that patients managed using PCT testing had less antibiotic exposure [21] , whereas other studies did not find such an effect [9, 22] . In addition, poor compliance with PCT testing guidelines or algorithms has been found in other studies at US institutions [8, 23] . Consistent with these previous studies, our study results suggest that the efficacy noted in trials that used PCT algorithms to guide antibiotic use in critically ill patients has not been well translated to the clinic, where availability of the PCT assay alone might not affect prescribing. Implementation strategies that might optimize the effect include embedded clinical decision support regarding evidence-based optimal cut points, restricted use of PCT testing in select subpopulations, and emphasis on serial testing.
Our analysis has limitations. The time-series analysis could have been affected by secular trends that might have changed antibiotic use, and the matched analysis might not have addressed all sources of confounding. For example, it is possible that the increased use observed in children for whom PCT was performed was a result of confounding by indication or severity of illness not measured by the clinical and demographic variables available in the database. The sensitivity analysis revealed that a small amount of unmeasured confounding could explain the increase risk of continuation for >72 hours. Also, we only had documentation that a PCT test was performed and were not able to determine if and when clinicians were aware of or considered the results. Last, the generalizability of our findings to other clinical settings, including for those in which the patients have a noncritical illness, is unclear.
In this study, introduction of the PCT assay into clinical practice without a standardized algorithm did not reduce antibiotic use at PICU admission. Whether rigorous application of a standardized PCT-guided algorithm, outside of a clinical trial, would affect antibiotic use requires additional study. 
